Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.

Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T.

Nat Genet. 2008 May;40(5):600-8. doi: 10.1038/ng.115. Epub 2008 Mar 30.

2.

Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles.

Bruder CE, Piotrowski A, Gijsbers AA, Andersson R, Erickson S, Diaz de Ståhl T, Menzel U, Sandgren J, von Tell D, Poplawski A, Crowley M, Crasto C, Partridge EC, Tiwari H, Allison DB, Komorowski J, van Ommen GJ, Boomsma DI, Pedersen NL, den Dunnen JT, Wirdefeldt K, Dumanski JP.

Am J Hum Genet. 2008 Mar;82(3):763-71. doi: 10.1016/j.ajhg.2007.12.011. Epub 2008 Feb 14.

3.

Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon.

Calcagno SR, Li S, Colon M, Kreinest PA, Thompson EA, Fields AP, Murray NR.

Int J Cancer. 2008 Jun 1;122(11):2462-70. doi: 10.1002/ijc.23383.

4.

Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer.

Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz AM, Kroh EM, Allen A, Fritz BR, Markowitz SD, Tewari M.

Oncogene. 2008 Jun 19;27(27):3880-8. doi: 10.1038/onc.2008.10. Epub 2008 Feb 11.

PMID:
18264139
5.

Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.

Biswas S, Trobridge P, Romero-Gallo J, Billheimer D, Myeroff LL, Willson JK, Markowitz SD, Grady WM.

Genes Chromosomes Cancer. 2008 Feb;47(2):95-106.

PMID:
17985359
6.

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ.

J Clin Oncol. 2007 Aug 1;25(22):3230-7.

PMID:
17664471
7.
8.

Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.

Muñoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, Sozmen EG, Madison BB, Pozzi A, Moon RT, Moses HL, Grady WM.

Cancer Res. 2006 Oct 15;66(20):9837-44.

9.

APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.

Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, Louvard D, Fodde R, Robine S.

Gastroenterology. 2006 Oct;131(4):1096-109. Epub 2006 Aug 16. Erratum in: Gastroenterology. 2006 Dec;131(6):2029.

PMID:
17030180
10.

Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo.

Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, Marsh V, Jamieson TJ, Guerra C, Ashton GH, Barbacid M, Clarke AR.

Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7. Epub 2006 Sep 7.

11.

TGF-beta and cancer.

Bierie B, Moses HL.

Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40. Epub 2005 Nov 10. Review.

PMID:
16289860
12.

TGF-beta signaling in T cells: roles in lymphoid and epithelial neoplasia.

Letterio JJ.

Oncogene. 2005 Aug 29;24(37):5701-12. Review.

PMID:
16123803
13.

Colorectal cancer: mutations in a signalling pathway.

Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE.

Nature. 2005 Aug 11;436(7052):792.

PMID:
16094359
14.

Tumour biology: senescence in premalignant tumours.

Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguría A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M.

Nature. 2005 Aug 4;436(7051):642.

15.

Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage.

Lee D, Pearsall RS, Das S, Dey SK, Godfrey VL, Threadgill DW.

Mol Cell Biol. 2004 Oct;24(20):8907-16.

16.

Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.

Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, Wirth PS, Gautam S, Moses HL, Grady WM.

Cancer Res. 2004 Jul 15;64(14):4687-92.

17.

Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T.

Cancer Cell. 2004 Apr;5(4):375-87.

18.

Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer.

Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB.

Nat Genet. 2004 Apr;36(4):417-22. Epub 2004 Mar 14.

PMID:
15034581
19.

TGFbeta and Wnt pathway cross-talk.

Attisano L, Labbé E.

Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):53-61. Review.

PMID:
15000149
20.

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia.

Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL.

Science. 2004 Feb 6;303(5659):848-51.

Supplemental Content

Support Center